New England Journal of Medicine· 2015Q1

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

Jan A. Burger, Alessandra Tedeschi, Paul M. Barr, Tadeusz Robak et al.

1,576citations
Q1SCImago
2015year

Short summary

Ibrutinib significantly improved progression-free survival (median not reached vs. 18.9 months) and overall survival (2-year rate 98% vs. 85%) compared to chlorambucil in previously untreated older patients with CLL/SLL.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Genetics

GeneticsMedicine